Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma (CITADEL-203)

被引：7
|
作者：
Lynch, Ryan C.
Paneesha, Shankara
Avigdor, Abraham
McKinney, Matthew S.
Wahlin, Bjorn E.
Hrom, John S.
Belada, David
Canales, Miguel
Cunningham, David
Devizzi, Liliana
Morley, Nicholas
Zheng, Fred
DeMarini, Douglas J.
Jiang, Wei
Trneny, Marek
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-134869
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma (CITADEL-203)
    Lynch, Ryan C.
    Paneesha, Shankara
    Avigdor, Abraham
    McKinney, Matthew S.
    Wahlin, Bjorn E.
    Hrom, John S.
    Belada, David
    Canales, Miguel
    Cunningham, David
    Devizzi, Liliana
    Morley, Nicholas
    Zheng, Fred
    DeMarini, Douglas J.
    Jiang, Wei
    Trneny, Marek
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 11 - 12
  • [2] Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma: Primary Analysis from a Phase 2 Study (CITADEL-203)
    Lynch, Ryan C.
    Avigdor, Abraham
    McKinney, Matthew S.
    Paneesha, Shankara
    Wahlin, Bjorn
    Hrom, John S.
    Cunningham, David
    Morley, Nicholas
    Canales, Miguel
    Bastos-Oreiro, Mariana
    Belada, David
    Devizzi, Liliana
    Zheng, Fred
    DeMarini, Douglas J.
    Jiang, Wei
    Trneny, Marek
    BLOOD, 2021, 138
  • [3] Parsaclisib, a PI3Kd inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study
    Trneny, Marek
    Avigdor, Abraham
    Mckinney, Matthew S.
    Paneesha, Shankara
    Wahlin, Bjorn E.
    Hrom, John S.
    Cunningham, David
    Morley, Nicholas
    Canales, Miguel
    Bastos-Oreiro, Mariana
    Belada, David
    Devizzi, Liliana
    Zheng, Fred
    Demarini, Douglas J.
    Jiang, Wei
    Jiang, Ping
    Lynch, Ryan C.
    ECLINICALMEDICINE, 2023, 63
  • [4] Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)
    Phillips, Tycel J.
    Corradini, Paolo
    Gurion, Ronit
    Patti, Caterina
    Tani, Monica
    Avigdor, Abraham
    Jurczak, Wojciech
    Mehta, Amitkumar
    Zinzani, Pier Luigi
    Lossos, Izidore S.
    Thieblemont, Catherine
    Zheng, Fred
    Rappold, Erica
    Zhao, Wanying
    Johnson, Peter
    BLOOD, 2020, 136
  • [5] Safety and efficacy of parsaclisib in combination with obinutuzumab and bendamustine in patients with relapsed or refractory follicular lymphoma (CITADEL-102): A phase 1 study
    Hamadani, Mehdi
    Coleman, Morton
    Boccia, Ralph
    Duras, Juraj
    Hutchings, Martin
    Zinzani, Pier Luigi
    Cordoba, Raul
    Oreiro, Mariana Bastos
    Williams, Vanessa
    Liu, Huiqing
    Stouffs, Michael
    Langmuir, Peter
    Sancho, Juan-Manuel
    HEMATOLOGICAL ONCOLOGY, 2023, 41 (05) : 848 - 857
  • [6] Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Previously Treated with Ibrutinib (CITADEL-205)
    Zinzani, Pier Luigi
    Delwail, Vincent
    Paneesha, Shankara
    Rule, Simon
    Garcia-Sancho, Alejandro Martin
    Marin-Niebla, Ana
    Salles, Gilles
    Sancho, Juan-Manuel
    Vergote, Vibeke
    Zilioli, Vittorio Ruggero
    Zheng, Fred
    DeMarini, Douglas J.
    Jiang, Wei
    Mehta, Amitkumar
    BLOOD, 2020, 136
  • [7] Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Not Previously Treated with a BTK Inhibitor (CITADEL-205)
    Mehta, Amitkumar
    Trneny, Marek
    Walewski, Jan
    Ribrag, Vincent
    Dartigeas, Caroline
    Christensen, Jacob Haaber
    Pane, Fabrizio
    Rodriguez, Guillermo
    Taszner, Michal
    Venugopal, Parameswaran
    Zilioli, Vittorio Ruggero
    Zheng, Fred
    DeMarini, Douglas J.
    Jiang, Wei
    Zinzani, Pier Luigi
    BLOOD, 2020, 136
  • [8] Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma: Primary Analysis from a Phase 2 Study (CITADEL-204)
    Phillips, Tycel
    Avigdor, Abraham
    Gurion, Ronit
    Patti, Caterina
    Corradini, Paolo
    Tani, Monica
    Mehta, Amitkumar
    Lossos, Izidore S.
    Lossos, Izidore S.
    Zinzani, Pier Luigi Luigi
    Thieblemont, Catherine
    Jurczak, Wojciech
    Zheng, Fred
    Rappold, Erica
    Zhao, Wanying
    Johnson, Peter
    BLOOD, 2021, 138
  • [9] Efficacy and Safety of Parsaclisib in Patients With Relapsed or Refractory Mantle Cell Lymphoma Not Previously Treated With a BTK Inhibitor: Primary Analysis From a Phase 2 Study (CITADEL-205)
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (02) : 11 - 13
  • [10] Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Not Previously Treated with a BTK Inhibitor: Primary Analysis from a Phase 2 Study (CITADEL-205)
    Mehta, Amitkumar
    Trneny, Marek
    Walewski, Jan
    Ribrag, Vincent
    Dartigeas, Caroline
    Christensen, Jacob Haaber
    Pane, Fabrizio
    Rodriguez, Guillermo
    Taszner, Michal
    Venugopal, Parameswaran
    Zilioli, Vittorio Ruggero
    Zheng, Fred
    DeMarini, Douglas J.
    Jiang, Wei
    Zinzani, Pier Luigi Luigi
    BLOOD, 2021, 138
12345